spacer
The Healthcare Sales & Marketing Network celebrates 22 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Xyrem 

 HSMN NewsFeed - 17 Feb 2020
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jan 2020
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 15 Nov 2019
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Jun 2019
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Nov 2018
Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Aug 2018
Vyxeos(R) Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Mar 2018
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Dec 2017
Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 May 2016
Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 13 Jan 2014
Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound For Excessive Daytime Sleepiness
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 26 Apr 2012
Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 24 Jan 2012
Jazz Pharmaceuticals plc Announces New Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jan 2012
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Dec 2008
Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations
Biopharmaceuticals
 HSMN NewsFeed - 11 Sep 2008
Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
Biopharmaceuticals
 HSMN NewsFeed - 13 Jul 2007
Jazz Pharmaceuticals Announces Settlement of Government Investigation
Biopharmaceuticals
 HSMN NewsFeed - 12 Mar 2007
New European Approval for Xyrem(R) Provides Significant Advance in the Treatment of Narcolepsy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Jan 2007
Jazz Pharmaceuticals Signs Licensing Agreement With Valeant Pharmaceuticals for Canadian Marketing Rights to Xyrem(R)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Jan 2007
Valeant Pharmaceuticals Signs Licensing Agreement for Canadian Rights to Xyrem(R) (Sodium Oxybate) from Jazz Pharmaceuticals
Biopharmaceuticals Licensing
 HSMN NewsFeed - 3 Oct 2006
UCB and Jazz Pharmaceuticals Announce Expansion of Xyrem(R) License Agreement to Include Fibromyalgia Syndrome
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Sep 2006
Jazz Pharmaceuticals Announces Phase III Clinical Trial to Study the Safety and Efficacy of Xyrem(R) (Sodium Oxybate) in Patients With Fibromyalgia Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 6 Mar 2006
Xyrem(R) (Sodium Oxybate) Now Available for the Treatment of Excessive Daytime Sleepiness (EDS) in Patients With Narcolepsy
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Feb 2006
Study Finds That Xyrem(R) (Sodium Oxybate) Relieves Pain in Patients With Fibromyalgia
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 8

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 8 additional stories matching:
Xyrem
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.